Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to a tax-free, all-stock merger that combines complementary neuroscience portfolios, with leadership consolidated under Supernus and Indivior shareholders receiving a special dividend at closing. The companies said the deal is expected to close in the fourth quarter of 2026, subject to regulatory approvals, and targets structural synergies and streamlined operations. The combined company will market a portfolio spanning addiction, ADHD, depression, and Parkinson’s disease, including Indivior’s Sublocade. Supernus brings established neuroscience assets such as FDA-approved apomorphine infusion therapy for Parkinson’s OFF episodes. The transaction is positioned around cost savings and R&D firepower rather than adding brand-new assets, setting up a clearer scale play in CNS therapeutics at a time when many peers are still working to translate mid-stage pipeline momentum into commercial outcomes.